CODIAK BIOSCIENCES INC (CDAK) Stock Price & Overview
NASDAQ:CDAK • US1920101060
Current stock price
The current stock price of CDAK is 0.057 USD. Today CDAK is down by -55.98%. In the past month the price decreased by -90.17%. In the past year, price decreased by -99%.
CDAK Key Statistics
- Market Cap
- 2.099M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.99
- Dividend Yield
- N/A
CDAK Stock Performance
CDAK Stock Chart
CDAK Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CDAK. When comparing the yearly performance of all stocks, CDAK is a bad performer in the overall market: 99.86% of all stocks are doing better.
CDAK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDAK. CDAK has a bad profitability rating. Also its financial health evaluation is rather negative.
CDAK Earnings
CDAK Forecast & Estimates
7 analysts have analysed CDAK and the average price target is 9.18 USD. This implies a price increase of 16005.26% is expected in the next year compared to the current price of 0.057.
For the next year, analysts expect an EPS growth of 41.06% and a revenue growth 61.58% for CDAK
CDAK Groups
Sector & Classification
CDAK Financial Highlights
Over the last trailing twelve months CDAK reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 44.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.66 |
CDAK Ownership
CDAK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 388.432B | ||
| AMGN | AMGEN INC | 16.04 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.29 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDAK
Company Profile
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
Company Info
IPO: 2020-10-14
CODIAK BIOSCIENCES INC
35 Cambridgepark Drive, Suite 500
Cambridge MASSACHUSETTS 02140 US
CEO: Douglas E. Williams
Employees: 102
Phone: 16179494100.0
CODIAK BIOSCIENCES INC / CDAK FAQ
What does CODIAK BIOSCIENCES INC do?
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
What is the current price of CDAK stock?
The current stock price of CDAK is 0.057 USD. The price decreased by -55.98% in the last trading session.
What is the dividend status of CODIAK BIOSCIENCES INC?
CDAK does not pay a dividend.
What is the ChartMill rating of CODIAK BIOSCIENCES INC stock?
CDAK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy CDAK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CDAK.
Can you provide the market cap for CODIAK BIOSCIENCES INC?
CODIAK BIOSCIENCES INC (CDAK) has a market capitalization of 2.10M USD. This makes CDAK a Nano Cap stock.
When does CODIAK BIOSCIENCES INC (CDAK) report earnings?
CODIAK BIOSCIENCES INC (CDAK) will report earnings on 2023-05-03.